Inhibition of SRC expression and activity inhibits tumor progression and metastasis of human pancreatic adenocarcinoma cells in an orthotopic nude mouse model.
about
SKI-606 (bosutinib), a novel Src kinase inhibitor, suppresses migration and invasion of human breast cancer cells.Dynamic interplay between adhesion surfaces in carcinomas: Cell-cell and cell-matrix crosstalkHepatocyte Growth Factor from a Clinical Perspective: A Pancreatic Cancer ChallengeAFAP-110 is overexpressed in prostate cancer and contributes to tumorigenic growth by regulating focal contactsMasitinib combined with standard gemcitabine chemotherapy: in vitro and in vivo studies in human pancreatic tumour cell lines and ectopic mouse model14-3-3sigma Modulates pancreatic cancer cell survival and invasivenessA phase 1 study of gemcitabine combined with dasatinib in patients with advanced solid tumors.Down-regulation of phospho-non-receptor Src tyrosine kinases contributes to growth inhibition of cervical cancer cells.The Src inhibitor dasatinib accelerates the differentiation of human bone marrow-derived mesenchymal stromal cells into osteoblastsAnomalous constitutive Src kinase activity promotes B lymphoma survival and growth.Antitumor activity of targeting SRC kinases in endothelial and myeloid cell compartments of the tumor microenvironmentCHIP is a novel tumor suppressor in pancreatic cancer through targeting EGFRPreferential antitumor effect of the Src inhibitor dasatinib associated with a decreased proportion of aldehyde dehydrogenase 1-positive cells in breast cancer cells of the basal B subtype.Development of orthotopic pancreatic tumor mouse modelsEnhanced sensitivity of pancreatic cancer cells to concurrent inhibition of aberrant signal transducer and activator of transcription 3 and epidermal growth factor receptor or Src.Simultaneous siRNA targeting of Src and downstream signaling molecules inhibit tumor formation and metastasis of a human model breast cancer cell line.Pancreatic cancer: molecular pathogenesis and new therapeutic targets.A functional nuclear epidermal growth factor receptor, SRC and Stat3 heteromeric complex in pancreatic cancer cellsErbB-inhibitory protein: a modified ectodomain of epidermal growth factor receptor synergizes with dasatinib to inhibit growth of breast cancer cells.Bosutinib reduces the efficacy of Dasatinib in triple-negative breast cancer cell lines.SRC: a century of science brought to the clinic.Src family kinase/abl inhibitor dasatinib suppresses proliferation and enhances differentiation of osteoblasts.Reciprocal regulation of c-Src and STAT3 in non-small cell lung cancer.Novel dual Src/Abl inhibitors for hematologic and solid malignancies.Curcumin enhances dasatinib-induced inhibition of growth and transformation of colon cancer cellsNicotine induces inhibitor of differentiation-1 in a Src-dependent pathway promoting metastasis and chemoresistance in pancreatic adenocarcinoma.Bosutinib plus capecitabine for selected advanced solid tumours: results of a phase 1 dose-escalation studyPre-clinical mouse models of human prostate cancer and their utility in drug discoveryCombined blockade of Src kinase and epidermal growth factor receptor with gemcitabine overcomes STAT3-mediated resistance of inhibition of pancreatic tumor growthOncogenic Ras/Src cooperativity in pancreatic neoplasia.Antiangiogenic and antitumor effects of SRC inhibition in ovarian carcinoma.Src inhibitors in suppression of papillary thyroid carcinoma growth.MiR-1178 promotes the proliferation, G1/S transition, migration and invasion of pancreatic cancer cells by targeting CHIP.Inhibition of c-Src tyrosine kinase prevents angiotensin II-mediated connexin-43 remodeling and sudden cardiac death.Phase I clinical trial of the Src inhibitor dasatinib with dacarbazine in metastatic melanomaMetabolic stress, reactive oxygen species, and arrhythmia.Dasatinib enhances antitumor activity of paclitaxel in ovarian cancer through Src signaling.Current knowledge on pancreatic cancer.Hematopoietic cell kinase (HCK) as a therapeutic target in immune and cancer cells.Src-signaling interference impairs the dissemination of blood-borne tumor cells
P2860
Q24656966-694489B6-A08B-4259-80DE-1FF4CE93B8C5Q26765201-5AF33504-0419-4343-8192-58209623A010Q26781273-ABF514C5-997A-41E4-930E-DE7B8D61298AQ28396630-10074D0B-9928-42ED-B3FD-48BCC1D27C2DQ28748653-CEB56288-8E00-4E5B-9DB7-0623FE9EF9A3Q33388611-99F17A6F-E589-482B-834D-72C66E7F1638Q33404541-494ACF71-D2C2-4720-AC85-9A9E5353B840Q33598877-849F5333-B2DD-42BC-B1A3-CBA22D969FB7Q33610879-37DAE3D8-532E-4A0A-BFAB-009C0D16F54BQ33623874-9B1445D8-92DA-48A7-B6F8-3690A22BC92DQ33638344-3814C378-2AEF-4A7A-8B15-09FCBEE5DE6CQ33688445-A63E7BED-39A3-4851-A490-6B72D6C998B6Q33722847-B551B9D4-4F70-4788-A622-93437106BF23Q33726528-6A7447BD-5CD6-4CDE-9FDC-051EC74AC2A9Q33861952-07BAD72F-6F8F-46F3-9FF5-0A7DE63AECD6Q33889288-A68A9F51-2624-4B3B-93C5-47D9B2EEC62CQ33899954-0ED6577C-2769-42C1-955F-E439A470B7AFQ33900776-4044DA14-083B-4C10-A945-4FC64F6AE71DQ33907679-580FC4AC-FDDA-4598-8593-966864F15A7BQ34026441-EC6F989F-F249-4753-A0A5-9351F69CD936Q34041298-E3B4A16D-A137-4821-9EBE-C135B681D998Q34067118-6F7580D7-4D96-4672-83E9-221E5DAE9B18Q34109397-9ECBD1E3-8D2F-4D9C-BCD2-C317F8A19704Q34121339-248080D1-5518-484A-82C9-33C3FB7EC387Q34126876-F87D7EF0-6D9D-438F-92EE-B75575AB7BF7Q34322085-AAA1F967-D3F8-4179-86C8-DD840CCE1CCCQ34658293-2D62DFF6-4469-44DB-8054-4A2484D93E5FQ34771567-F7E1850F-60B9-4C84-A082-894B0A0C0FE9Q34812100-AD1EB5F7-F999-48C3-BB79-5CADE5E0E000Q35015392-9822B5DE-C874-43EF-9F0B-E6DFFABA0015Q35456086-228D2D22-E00E-4167-A12E-C081EC77964BQ35457965-CF3DA008-19F7-4B64-9680-894D2F536505Q35551998-098B5FD5-680C-444A-B29C-E9824D289DD6Q35580826-B53CA4B7-527F-48F5-9560-F593329EA452Q35653813-31D6128B-F01A-408D-9798-5726E87DF0F9Q35690954-75AAA29A-E989-453F-A844-AF0E92551334Q35919774-D0A304E4-2AC3-4B4E-BDEE-F78EDF7F5FD5Q35971808-6EE501BF-019C-4460-A8A6-C5711A3E5DFAQ36140620-E824268E-2301-47F4-AA51-A972765309B7Q36153123-161A8CB5-AB98-4F6A-A496-BF60583B6930
P2860
Inhibition of SRC expression and activity inhibits tumor progression and metastasis of human pancreatic adenocarcinoma cells in an orthotopic nude mouse model.
description
2006 nî lūn-bûn
@nan
2006 թուականի Մարտին հրատարակուած գիտական յօդուած
@hyw
2006 թվականի մարտին հրատարակված գիտական հոդված
@hy
2006年の論文
@ja
2006年論文
@yue
2006年論文
@zh-hant
2006年論文
@zh-hk
2006年論文
@zh-mo
2006年論文
@zh-tw
2006年论文
@wuu
name
Inhibition of SRC expression a ...... n orthotopic nude mouse model.
@ast
Inhibition of SRC expression a ...... n orthotopic nude mouse model.
@en
type
label
Inhibition of SRC expression a ...... n orthotopic nude mouse model.
@ast
Inhibition of SRC expression a ...... n orthotopic nude mouse model.
@en
prefLabel
Inhibition of SRC expression a ...... n orthotopic nude mouse model.
@ast
Inhibition of SRC expression a ...... n orthotopic nude mouse model.
@en
P2093
P2860
P1476
Inhibition of SRC expression a ...... n orthotopic nude mouse model.
@en
P2093
Cheryl H Baker
David S Hong
Donald P Lesslie
Francis Y Lee
Gary E Gallick
James L Abbruzzese
Jose G Trevino
Justin M Summy
Nicholas J Donato
Nila U Parikh
P2860
P304
P356
10.2353/AJPATH.2006.050570
P407
P577
2006-03-01T00:00:00Z